In stunning twist, FDA approves Sarepta's Duchenne drug it rejected

In stunning twist, FDA approves Sarepta's Duchenne drug it rejected

Submitted by admin on December 13, 2019 - 12:28pm
Source: 
Biopharma Dive
News Tags: 
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Headline: 
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
snippet: 

The Food and Drug Administration on Thursday approved Sarepta's Duchenne muscular dystrophy therapy Vyondys 53, four months after rejecting the drug over safety concerns. 

Do Not Allow Advertisers to Use My Personal information